US4529594A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Protein having antitumor activity
Assignee: Asahi Kasei Corp
•
Filing: 1984-07-11
•
Granted: 1985-07-16
•
Expires: 2004-07-11
Abstract
Abstract A protein having a polypeptide subunit containing an N-terminal amino acid sequence of Ser-Ala-Ser-Arg-Ala-Leu-Ser-Asp-Lys-Pro-Leu-Ala-His-Val-Val-Ala-Asn-Pr o-Gln-Val-Glu-Gly-Gln-Leu-Gln-Trp-Leu. The protein of the present invention is obtained in substantially pure form at high activity recovery, and is excellent in inducing necrosis of tumors with no toxicity upon the normal tissues of the living body. The protein of the present invention is thermally stable and, therefore, when preparation of pharmaceutical compositions is conducted, the protein of the present invention can be stably formulated into compositions.
Inventors
- 👤 Hiroshi Hayashi
- 👤 Junji Kuwashima
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 19:15
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/46; C07K14/47; A; A61; A61P; A61P35/00; C07K14/52; C07K14/525; Y; Y10; Y10S; Y10S530/00; Y10S530/82; Y10S530/825; Y10S530/827; Y10S530/828; Y10S530/829; Y10S530/83
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
152 words
A protein having an antitumor activity comprising a polypeptide subunit having an N-terminal amino acid sequence of the following formula (I): Ser-Ala-Ser-Arg-Ala-Leu-Ser-Asp-Lys-Pro-Leu-Ala-His-Val-Val-Ala-Asn-Pro-Gln-Val-Glu-Gly-Gln-Leu-Gln-Trp-Leu- wherein Ala stands for alanine residue, Arg an arginine residue, Asn an asparagine residue, Asp an aspartic acid residue, Gln a glutamine residue, Glu a glutamic acid residue, Gly a glycine residue, His a histidine residue, Leu a leucine residue, Lys a lysine residue, Pro a proline residue, Ser a serine residue, Trp a tryptophan residue and Val a valine residue; and which protein has: (a) a molecular weight of 40,000±5,000 in terms of a value as measured by a gel filtration method as defined herein and a molecular weight of 17,500±2,000 in terms of a value as measured by an SDS-polyacrylamide gel electrophoresis method as defined herein; and (b) an isoelectric point of 5.0±0.3 in terms of a value as measured by an isoelectric focusing method as defined herein.
Claim 2
Dependent Claim
152 words
A protein having an antitumor activity comprising a polypeptide subunit having an N-terminal amino acid sequence of the following formula (I): Ser-Ala-Ser-Arg-Ala-Leu-Ser-Asp-Lys-Pro-Leu-Ala-His-Val-Val-Ala-Asn-Pro-Gln-Val-Glu-Gly-Gln-Leu-Gln-Trp-Leu- wherein Ala stands for alanine residue, Arg an arginine residue, Asn an asparagine residue, Asp an aspartic acid residue, Gln a glutamine residue, Glu a glutamic acid residue, Gly a glycine residue, His a histidine residue, Leu a leucine residue, Lys a lysine residue, Pro a proline residue, Ser a serine residue, Trp a tryptophan residue and Val a valine residue; and which protein has: (a) a molecular weight of 40,000±5,000 in terms of a value as measured by a gel filtration method as defined herein and a molecular weight of 17,500±2,000 in terms of a value as measured by an SDS-polyacrylamide gel electrophoresis method as defined herein; and (b) an isoelectric point of 5.0±0.3 in terms of a value as measured by an isoelectric focusing method as defined herein.
Claim 3
Dependent Claim
23 words
A substantially pure protein having an antitumor activity comprising the polypeptide subunit having the N-terminal amino acid sequence as defined in claim 1.
Claim 4
Dependent Claim
24 words
A pharmaceutical composition comprising an effective antitumor amount of a protein of claim 1 and at least one pharmaceutically acceptable carrier, diluent or excipient.
Claim 5
Dependent Claim
24 words
A pharmaceutical composition comprising an effective antitumor amount of a protein of claim 2 and at least one pharmaceutically acceptable carrier, diluent or excipient.
Claim 6
Dependent Claim
20 words
A method for treating tumors by administering to a host an effective antitumor amount of a protein of claim 1.
References Cited (Backward Citations)
US4076701A
Cited
US4457863A
Cited
US4309418A
Cited
US4405608A
Cited
EP0090892A1
Cited
US4447355A
Cited
US4390468A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-07-15 | 1989-01-14 | 1989-07-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-07-15 | 1993-01-14 | 1993-07-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-07-15 | 1997-01-14 | 1997-07-16 | $7700.00 | Window Closed / Lapsed |